Forte Biosciences Prices $150M Public Offering
Analysis based on 7 articles · First reported Apr 08, 2026 · Last updated Apr 09, 2026
The market is impacted positively by Forte Biosciences' public offering, as it provides capital for the company's clinical development and research activities, potentially leading to future growth. The offering is expected to raise approximately $150 million, which could strengthen Forte Biosciences' financial position.
Forte Biosciences, a clinical-stage biopharmaceutical company, announced the commencement and pricing of a public offering of 5,709,936 shares of its common stock at $26.27 per share. The company also granted underwriters a 30-day option to purchase an additional 856,490 shares. The offering is expected to generate approximately $150 million in gross proceeds, which Forte Biosciences intends to use for working capital, general corporate purposes, and funding the clinical development of its product candidate FB102 and other research activities. Guggenheim Securities and Barclays are acting as joint book-running managers for the offering, which is expected to close around April 10, 2026, subject to customary closing conditions. The offering is being made pursuant to a Registration Statement on Form S-3 filed with the United States===U.S. Securities and Exchange Commission.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard